Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024

Rhea-AI Summary

Lumos Pharma, Inc. (NASDAQ:LUMO) announced that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society (APPES 2024). The event will take place from October 2-5, 2024, in New Delhi, India.

The presentation, scheduled for October 3rd, will focus on the evaluation of oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD). Professor Paul Hofman, MD, from the Liggins Institute, University of Auckland, New Zealand, will deliver the presentation titled 'Growth, IGF-1 and IGFBP-3 Responses to the Oral Growth Hormone (GH) Secretagogue, LUM-201, in Paediatric Growth Hormone Deficiency (PGHD) in the OraGrowtH210 Trial'.

Positive

• Phase 2 clinical trial data accepted for presentation at a major international conference
• Potential advancement in treatment for Pediatric Growth Hormone Deficiency (PGHD)
• Increased visibility for Lumos Pharma's research in the pediatric endocrinology community

Negative

• None.

AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, or APPES 2024, to be held October 2-5, 2024 in New Delhi, India. This analysis of data from the OraGrowtH210 Trial evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on October 3^rd by Professor Paul Hofman, MD, Liggins Institute, University of Auckland, Auckland, New Zealand.

Abstract Presentation: Thursday, October 3^rd – Oral Session: Growth & Puberty – 2:30PM Local Time

• Abstract entitled, Growth, IGF-1 and IGFBP-3 Responses to the Oral Growth Hormone (GH) Secretagogue, LUM-201, in Paediatric Growth Hormone Deficiency (PGHD) in the OraGrowtH210 Trial (Paul Hofman, MD, et al)
  

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.

FAQ

What is the main focus of Lumos Pharma's presentation at APPES 2024?

The presentation will focus on updated analysis of data from the Phase 2 OraGrowtH210 clinical trial, evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD).

When and where will Lumos Pharma (LUMO) present its clinical trial results?

Lumos Pharma will present its clinical trial results on October 3rd, 2024, at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society (APPES 2024) in New Delhi, India.

Who will be presenting Lumos Pharma's (LUMO) clinical trial data at APPES 2024?

Professor Paul Hofman, MD, from the Liggins Institute, University of Auckland, New Zealand, will be presenting Lumos Pharma's clinical trial data at APPES 2024.

What is the title of Lumos Pharma's (LUMO) presentation at APPES 2024?

The presentation is titled 'Growth, IGF-1 and IGFBP-3 Responses to the Oral Growth Hormone (GH) Secretagogue, LUM-201, in Paediatric Growth Hormone Deficiency (PGHD) in the OraGrowtH210 Trial'.